Related Experiment Videos
Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy
1University of Alabama Medical School, Faculty Office Towers, 510 20th Street South, Room 702, Birmingham, AL 35294, USA. dshbell@uab.edu
Clinical Therapeutics
|January 11, 2005
Summary
Sulfonylureas are common oral antidiabetic agents. This review provides guidelines for transitioning patients between sulfonylureas or to combination therapy for type 2 diabetes mellitus management.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Oral antidiabetic agents are first-line therapy for type 2 diabetes mellitus.
- Understanding agent efficacy and side effects is crucial for effective treatment strategies.
Purpose of the Study:
- Review sulfonylurea efficacy and adverse events.
- Provide guidelines for transitioning patients between sulfonylureas or to combination therapy.
Main Methods:
- Comprehensive literature search (MEDLINE, PubMed) from 1966 to present.
- Reviewed clinical trial abstracts for dosing conversion and equivalence data.
- Developed strategies for safe and effective sulfonylurea switching and combination therapy initiation.
Main Results:
- Monitoring for hypoglycemia, fasting serum glucose, and glycosylated hemoglobin is essential during therapy transitions.
- Patients not achieving adequate control on monotherapy should be considered for combination therapy.
Conclusions:
- Transitioning to combination therapy can improve patient compliance.
- Combination therapy may lead to cost savings and enhanced glycemic control in diabetic patients.